Experts from the World Health Organization said on the 26th that China National Pharmaceutical Group and China Kexing Company have submitted data related to the two coronavirus vaccines they have developed to WHO for the evaluation of the WHO emergency use list, which the organization appreciates.
Catherine O’Brien, WHO’s head of immunization, vaccines and biological products, said at a press conference on the same day that two kinds of Chinese vaccine products are currently being evaluated by the WHO emergency use list, namely, the inactivated coronavirus vaccine from China National Pharmaceutical Group and China Kexing Company.
O’Brien said that WHO also expects China’s coronavirus vaccine data to be evaluated through the organization’s policy.
Unlike the emergency use list assessment from the WHO Vaccine Regulatory Branch, the policy assessment is conducted separately by the WHO Strategic Advisory Group on Immunization and will make recommendations on how to use the relevant vaccines.
Previously, the expert group has conducted a policy evaluation and recommendations on the use of Pfizer and Modena’s vaccines.
According to the latest WHO documents, the vaccine of China National Pharmaceutical Group is in the process of the WHO emergency use list assessment process.
Kexing Company submitted vaccine evaluation data in mid-January, and more documents are expected to be submitted by the end of this month. The final evaluation results of the two vaccines are expected to be released as early as March.
In addition, Seth Berkeley, CEO of the Global Alliance for Vaccines and Immunization, praised China’s efforts on the coronavirus vaccine at the press conference. He said that China had joined the WHO-led COVID-19 Vaccine Implementation Plan (COVAX) very early on.”
China has submitted some data on (coronavirus) vaccines to the WHO for pre-qualification. This step is very important, and we will continue to talk with China.
If people are interested in obtaining these vaccines and the data also show that they can bring value to the (COVAX) vaccine product portfolio, we will promote cooperation with these (Chinese) companies. Berkeley said.
